CD28 and diffuse large B-cell lymphoma: The results showed that genes in the antitumor immunity pathways, such as antigen processing ubiquitination proteasome degradation, NOD 1/2 signaling, T cell receptor signaling, B cell receptor signaling, costimulation by the CD28 family, and TNF signaling, were upregulated in the low-risk DLBCL patients (Figure 6).